Evidence map›Paper›PMID 32052719›Full record

SynthesisEpidemiology and infection2020

The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis.

M Tin Tin Htar, M S Yerramalla, J C Moïsi, D L Swerdlow

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Epidemiology and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  12. Article
  13. Article
  14. Article
  15. Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M Tin Tin HtarMedical Development, Scientific and Clinical Affairs, Pfizer Inc., Paris, France.ORCID 0000-0002-6148-3101
M S YerramallaEpidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Institut National de la Santé et de la recherche Médicale (INSERM) U 1153 and Centre of Research in Epidemiology and Statistics (CRESS), Paris, France.
J C MoïsiMedical Development, Scientific and Clinical Affairs, Pfizer Inc., Paris, France.
D L SwerdlowMedical Development, Scientific and Clinical Affairs, Pfizer Inc., Collegeville, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is the most common pathogen associated with acute lower respiratory tract infections in young children. RSV is also a major viral pathogen causing severe lung disease in the adult population, particularly among the elderly. We conducted a review of adult RSV studies published from January 1970 to February 2017 to determine the burden of disease among adults worldwide. There were no restrictions on health care setting or definition of RSV infection. A total of 1530 published studies were identified, 95 of which were included in this review. The incidence rates of hospitalised RSV acute respiratory tract infection (ARI) in adults >65 years old ranged from 7.3 to 13.0/105 population in Africa and Asia and from 190 to 254/105 population in the USA. Higher incidence rates (195-1790/105 population) were observed in adults ≥50 years old for outpatient or emergency visits in the USA. Of all ARI patients, RSV accounted for 1-10% in adults and 2-14% in patients with chronic diseases or transplantation. Given the limitations in the existing data, significant efforts should be made to generate evidence on the burden of RSV infections in adults and to estimate the potential impact of future preventive interventions.

Indexed as

Cost of IllnessAdolescentAdultAgedAged, 80 and overFemaleGlobal HealthHospitalizationHumansIncidenceMaleMiddle AgedRespiratory Syncytial Virus InfectionsYoung AdultAcute respiratory infectionepidemiologyrespiratory syncytial virussurveillance

Identifiers

PMID32052719
PMCPMC7078512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.